About Magnitude Biosciences
Magnitude Biosciences is a Healthcare company based in Durham (United Kingdom) founded in 2018. Cell-free in vitro assays are supplied to drug discovery firms. Magnitude Biosciences has raised $3.68 million across 7 funding rounds from investors including Maven Capital Partners, UK Research and Innovation and European Union. The company has 12 employees. Magnitude Biosciences offers products and services including C. elegans Assays and WormGazerâ„¢ Technology. Its focus areas include Life Sciences, Life Sciences Platforms and Tools, Research Services and Drug Discovery. Its legal entity is MAGNITUDE BIOSCIENCES LIMITED.
Company details
Magnitude Biosciences was established in 2018 in Durham, United Kingdom, within the biotechnology sector. Cell-free in vitro assays based on C. elegans models are delivered to support drug discovery efforts. Operations encompass prescreening of compounds to mitigate risks in mammalian studies, along with screening of mutant libraries and compound collections for targeted evaluations.
- Headquarters Durham, United Kingdom
- Employees 12
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website magnitudebiosciences.com
- Social LinkedIn X Facebook
- Legal Name Magnitude Biosciences Limited
- Total Equity Funding$3.68M (USD)
in 7 rounds
- Latest Funding Round$1.73M (USD), Series A
Sep 2026
- InvestorsMaven Capital Partners
& 4 more
- Employee Count12
Products & Services of Magnitude Biosciences
Magnitude Biosciences offers a comprehensive portfolio of products and services, including C. elegans Assays and WormGazer™ Technology.
Customized studies for drug efficacy and toxicity testing
Tool for monitoring worm mobility in biological research
Funding Insights of Magnitude Biosciences
Magnitude Biosciences has successfully raised a total of $3.68M across 7 strategic funding rounds. The most recent funding activity was a Series A round of $1.73 million completed in September 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $3.68M
- Total Rounds 7
- Last Round Series A — $1.73M
- First Round $192,930
(Jan 2019)
- Investors Count 5
All 7 funding rounds of Magnitude Biosciences with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep 2026 | $1.73M | Series A | – | Northstar Ventures | |
| May 2025 | Grant | – | – | ||
| May 2025 | $943,586 | Seed | – | – | |
| Nov 2022 | Seed | – | European Union, Northstar Ventures | – | |
| Aug 2020 | $329,697 | Seed | – | Saker Capital, Northstar Ventures | – |
| Dec 2019 | $484,815 | Seed | – | Northstar Ventures | |
| Jan 2019 | $192,930 | Seed | – | Saker Capital, Northstar Ventures | – |
5 investors in total: 5 institutional.
Investors in Magnitude Biosciences
Magnitude Biosciences has secured backing from 5 investors, including institutional and venture fund investors. Prominent investors backing the company include Maven Capital Partners, UK Research and Innovation and European Union.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Early-stage investments are made in UK companies across diverse sectors. | northstarventures.co.uk | Newcastle Upon Tyne, United Kingdom | ||
Multiple sectors are targeted for private equity investments. | 2005 | mavencp.com | Birmingham, United Kingdom | |
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability | 1958 | europa.eu | Brussels, Belgium | |
Investment consulting services are provided by Saker Capital in Dubai. | 2006 | sakercapital.com | Dubai, United Arab Emirates | |
Research and innovation funding is managed for UK advancement. | 2018 | ukri.org | Swindon, United Kingdom |
Investor details for Magnitude Biosciences
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Magnitude Biosciences
4 people are tracked at Magnitude Biosciences (2 in leadership, 2 in team); the tracked headcount is 12.
| Name | Role | Group |
|---|---|---|
Fozia Saleem | Chief Executive Officer | Leadership |
Sara Allan | Head of Operations | Leadership |
Matthew Bell | Program Manager / Hardware Engineer | Team |
Frederique Gill | Commercial Innovation Manager | Team |
Complete people profiles for Magnitude Biosciences
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Magnitude Biosciences
3 dated milestones of Magnitude Biosciences across 8 years, from founding to its latest funding, stage changes and deals.
- Founded Magnitude Biosciences is founded.
- Funding First funding round of $193K.
- Funding Latest funding round, Series A, of $1.7M.
Top companies in Life Sciences Platforms & Tools
3 companies that operate in the same segment as Magnitude Biosciences (Life Sciences Platforms & Tools) in United Kingdom, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.34 B | USD 301.49 M | 1,372 | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | |||
Biological reagents and antibodies are developed for life science research. | 1998 | Cambridge, Cambridgeshire, United Kingdom | USD 78.8 M |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Magnitude Biosciences
Complete news archive for Magnitude Biosciences
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Magnitude Biosciences
Magnitude Biosciences was founded in 2018 and raised its 1st funding round 1 year after it was founded.
Magnitude Biosciences is headquartered in Durham, United Kingdom.
Magnitude Biosciences is a funded company, having raised a total of $3.68M across 7 funding rounds to date. The company's 1st funding round was a Seed of $192.93K, raised on Jan 2019.
Magnitude Biosciences has 12 employees.
Magnitude Biosciences was established in 2018 in Durham, United Kingdom, within the biotechnology sector. Cell-free in vitro assays based on C. elegans models are delivered to support drug discovery efforts. Operations encompass prescreening of compounds to mitigate risks in mammalian studies, along with screening of mutant libraries and compound collections for targeted evaluations.
Magnitude Biosciences offers C. elegans Assays and WormGazerâ„¢ Technology.
Magnitude Biosciences has 5 investors. Key investors include Maven Capital Partners, UK Research and Innovation, European Union, Saker Capital, and Northstar Ventures.
Magnitude Biosciences operates through Magnitude Biosciences Limited.